T. Rowe Price Investment Management
IMNM icon

T. Rowe Price Investment Management’s Immunome IMNM Stock Holding History

T. Rowe Price Investment Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417M Buy
19,676,883
+3,312,872
+20% +$70.9M 0.27% 94
2026
Q1 		$358M Buy
16,364,011
+2,942,024
+22% +$65.5M 0.25% 99
2025
Q4 		$288M Buy
13,421,987
+5,003,824
+59% +$87.8M 0.18% 132
2025
Q3 		$98.6M Buy
8,418,163
+142,906
+2% +$1.42M 0.06% 272
2025
Q2 		$77M Buy
8,275,257
+720,663
+10% +$5.91M 0.05% 324
2025
Q1 		$50.8M Buy
7,554,594
+2,054,640
+37% +$19.7M 0.03% 389
2024
Q4 		$58.4M Sell
5,499,954
-262,059
-5% -$3.17M 0.04% 385
2024
Q3 		$84.2M Buy
5,762,013
+1,883,418
+49% +$26.8M 0.05% 327
2024
Q2 		$46.9M Buy
3,878,595
+2,362,141
+156% +$37M 0.03% 395
2024
Q1 		$37.4M Buy
+1,516,454
New +$30.8M 0.02% 440

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management's IMNM Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Immunome (IMNM) stake by 20% in Q2 2026, buying an estimated $70.9M and bringing the position to 19,676,883 shares worth $417M. The position accounts for 0.27% of the portfolio, ranked #94.

T. Rowe Price Investment Management first reported a position in IMNM in Q1 2024 and has held it in 10 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • T. Rowe Price Investment Management held 19,676,883 shares of Immunome worth $417M as of Q2 2026.
  • T. Rowe Price Investment Management bought 3,312,872 Immunome shares in Q2 2026, an estimated $70.9M.
  • Immunome made up 0.27% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #94 holding.
  • T. Rowe Price Investment Management first reported a position in Immunome in Q1 2024 and has held it in 10 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.